On the stock market since 1980, it operates in the world of health and science. It has 23,200 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 27% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 28 buys and 18 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $15.60 — 482% above today’s price.
A loss of $1.1B against $2.8B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, OMI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OMI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.